BRAF and cancer: As BRAF mutant/MSS cancers have a constitutively active MAPK pathway, loss of the SMAD loci may be redundant and could help to explain the significantly lower rate of deletion found at the 18q region in these compared to BRAF wild type/MSS cancers.